Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Suresh Siddhanti"'
Autor:
Sidney H. Schnoll, Mary Tagliaferri, Suresh Siddhanti, Lin Lu, Jeffrey A Gudin, Carlo J Di Fonzo, Joseph Gimbel, Nathaniel P. Katz, Richard Rauck, Stephen K. Doberstein, Jack E. Henningfield
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
ObjectiveTo evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist.DesignPhase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low
Autor:
Mary Tagliaferri, Lin Lu, Martin E. Hale, John D. Markman, Jeffrey Potts, Joseph Gimbel, Jim M. Wild, Margit Cecile Tagliaferri, Charles Argoff, Jeffrey Gudin, Nathaniel P. Katz, Eva Agaiby, Suresh Siddhanti, Richard Rauck, Stephen K. Doberstein
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
Objective To evaluate the long-term safety of NKTR-181, a novel mu-opioid receptor agonist that may have reduced human abuse potential, in patients with moderate to severe chronic low back pain (CLBP) or other chronic noncancer pain (CNP). Design Unc
Autor:
Roi Treister, Stephen K. Doberstein, Harrison Elder, Nathalie Erpelding, Nathaniel P. Katz, Ryan K. Lanier, Jack E. Henningfield, Richard Rauck, Mary Tagliaferri, Lin Lu, Suresh Siddhanti, Joseph Gimbel, Jeffrey A Gudin, Carlo J Di Fonzo
Publikováno v:
Current Medical Research and Opinion. 35:1513-1522
Objective: To prospectively evaluate the abuse potential of NKTR-181, a novel opioid analgesic, in two phase 3 clinical trials using a newly developed reporting system: the Misuse, Abuse, a...
Autor:
John D. Markman, Joseph Gimbel, Michael C. Rowbotham, Charles Argoff, Eva Agaiby, Suresh Siddhanti, Jeffrey A Gudin, Stephen K. Doberstein, Nathaniel P. Katz, Richard Rauck, Martin E. Hale, Mary Tagliaferri, Lin Lu
Publikováno v:
Pain
Supplemental Digital Content is Available in the Text. NKTR-181 provides effective analgesia in patients with moderate-to-severe chronic low-back pain with low incidence of central nervous system side effects.
NKTR-181, a new molecular entity, m
NKTR-181, a new molecular entity, m
Autor:
Jack E. Henningfield, Lin Lu, Lynn R. Webster, Carlo J Di Fonzo, Aleksandrs Odinecs, August R. Buchhalter, Suresh Siddhanti, Michael A Eldon
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
Objective Evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of NKTR-181, a novel mu-opioid agonist molecule, relative to oxycodone. Design This randomized, single-center, double-blind, active- and placebo-controlled f
Autor:
Michael A Eldon, Suresh Siddhanti, Jack E. Henningfield, Carlo J Di Fonzo, Mary Tagliaferri, Lin Lu, Ute Hoch, Janet Jobes, Jonathan Zalevsky, Stephen K. Doberstein, Margaret Ziola, Debra Kelsh, Bradley Vince, Sunny Xie, Ge Xue
Publikováno v:
Pain Medicine.
ObjectiveTo evaluate the human abuse potential, pharmacokinetics, pharmacodynamics, and safety of oral NKTR-181 (oxycodegol), a novel full mu-opioid receptor agonist, relative to oral oxycodone.DesignThis double-blind, randomized, single-dose, crosso
Autor:
Daniel Dickerson, Lin Lu, Christie Fanton, Suresh Siddhanti, Brian Kotzin, Neha Dixit, Jonathan Zalevsky, Toufigh Gordi
Publikováno v:
Oral Presentations.
Background Impaired IL-2 production and dysfunction of regulatory T cells (Tregs) have been identified as key immunological defects leading to the breakdown of immune self-tolerance, a causative mechanism implicated in multiple autoimmune diseases. E
Autor:
R. Levin, Suresh Siddhanti, Vishala Chindalore, Jonathan Zalevsky, Lin Lu, R. Furie, Brian Kotzin, Neha Dixit, Christie Fanton, I. Diab
Publikováno v:
Annals of the Rheumatic Diseases. 79:238.2-239
Background:Impaired IL-2 production and dysfunction of regulatory T cells (Tregs) have been identified as key immunological defects leading to the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can expand Tregs, but the effect is limited by
Autor:
Michael H. Davidson, Suresh Siddhanti, Angelina V. Ciaccia, Cheryl A. Keech, Pandurang M. Kulkarni, William Insull
Publikováno v:
Metabolism. 54:939-946
Raloxifene and low-dose simvastatin can each reduce low-density lipoprotein (LDL) cholesterol without affecting high-density lipoprotein (HDL) cholesterol and triglycerides. The objective of this double-blind, 12-week study is to determine whether ra
Autor:
Stefan Goemaere, Steven R. Cummings, John L. Stock, Adolfo Diez-Perez, Yongming Qu, Richard Eastell, Jose R. Zanchetta, Steven T. Harris, Jingli Song, Suresh Siddhanti, Ethel S. Siris, Pandurang M. Kulkarni, Mayme Wong
Publikováno v:
Journal of Bone and Mineral Research. 20:1514-1524
In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE had limitations for assessing fracture risk. In a subset of 386 women, 7